Background: Two types of Mentalization-Based Treatment (MBT) have been developed and empirically evaluated for borderline personality disorder (BPD): Day Hospital MBT (MBT-DH) and
Introduction
Borderline personality disorder (BPD) is a highly prevalent mental disorder that is associated with a high socioeconomic burden (1) . Psychotherapy is the treatment of choice for BPD patients (2-4).
Mentalization-Based Treatment (MBT, 5) is one of the empirically validated psychotherapies for BPD.
MBT is based on the assumption that key features of BPD, such as impulsivity, affect dysregulation, and problems in interpersonal relationships, are related to impairments in mentalizing, that is, the ability to understand the actions of other people and oneself in terms of mental states (e.g., needs, thoughts, feelings, wishes, and desires) (5). The main goal of MBT is to help patients develop robust mentalizing skills within everyday interpersonal interactions, to improve affect regulation and interpersonal functioning.
Two types of MBT for BPD have been developed and evaluated in randomized controlled trials (RCTs) and naturalistic outcome studies: Day Hospital MBT (MBT-DH; 6, 7-10) and Intensive Outpatient MBT (MBT-IOP; 11, 12-14). MBT-DH and MBT-IOP are identical in length (with a maximum duration of 18 months) and consist of the same number of individual treatment sessions, but they differ markedly in the frequency of group psychotherapy (Table 1) . Given the large differences in the intensity and thus costs of the two treatment programmes, there is an urgent need for studies directly comparing them. A direct head-to-head comparison of MBT-DH and MBT-IOP has not yet been conducted. The current study was designed to fill this gap. We present treatment outcome results 18 months after start of treatment of a multicentre RCT comparing MBT-DH and MBT-IOP in BPD patients. We hypothesized that patients in both treatment programmes would show significant improvements on primary and secondary outcomes. Because of its greater treatment intensity, MBT-DH was expected to be superior to MBT-IOP (defined in terms of a between-group difference of Cohen's d≥0.5) on the primary outcome of symptom severity at 18 months as measured with the Brief Symptom Inventory (BSI; 15, 16) . Secondary outcomes included measures of borderline symptomatology, personality functioning, interpersonal functioning, quality of life, and self-harm.
[Insert Table 1 ]
Method
This study was approved by the Medical Ethical Committee of Erasmus Medical Center, Rotterdam, the Netherlands (NL38571.078.12). The design of the study has been described in detail elsewhere (1) . Inclusion criteria were (a) BPD diagnosis, (b) age ≥18 years, (c) adequate mastery of the Dutch language, and (d) travel time to the MBT ward of <1 hour. Exclusion criteria were (a) a diagnosis of autism spectrum disorder, chronic psychotic disorder, or organic brain disorder that interferes significantly with the ability to mentalize; (b) intellectual disability (IQ <80); or (c) a diagnosis of antisocial personality disorder with a history of physical violence. Because of ethical considerations, patients who had a stable job for at least 2 years for a minimum of 15 hours a week and/or were primary caregivers of children under 4 years of age could agree to either be randomized into the study or enter MBT-IOP directly, in which case they were excluded from the trial. After providing written informed consent, patients were assessed for symptom and personality disorders using the Structured Clinical Interview for DSM-IV Axis I and Axis II disorders (SCID-I, SCID-II; 17, 18) , administered by trained MSc-level psychologists. Patients who were excluded or refused to participate in the trial were ideally referred to an alternative evidence-based treatment delivered within the participating sites. Participating patients were then randomly allocated to either MBT-DH or MBT-IOP by an independent researcher, based on a 1:1 computerized randomization algorithm. However, because of insufficient capacity to provide alternative treatments within the treatment sites, patients who refused participation in the trial had to be allocated to MBT-IOP more often than anticipated. This consumed part of the IOP trial capacity and we subsequently decided to adjust the randomization algorithm in agreement with the Trial Steering Committee, taking into account available treatment places to prevent ethically unacceptable long waiting periods while assuring random allocation. Yet, this still resulted in a skewed randomization between the treatments. However, the average waiting period before starting both treatments was 4.3 months (SD = 2.4 months), and was not significantly different between the two treatment groups. Two sites that had originally intended to participate in the trial were excluded because they were unable to implement MBT in a timely fashion, resulting in the recruitment of patients at three treatment sites (de Viersprong Amsterdam, de Viersprong Bergen op Zoom, and the Netherlands Psychoanalytic Institute). Recruited patients completed an assessment battery before randomization, at the start of treatment, and at 6-month intervals up to 36 months after the start of treatment.
Treatment interventions
MBT focuses on improving BPD patients' capacity for mentalizing (19) . Mentalizing is thought to play a key role in affect regulation and interpersonal relationships (5, 20, 21) . Treatment components and features in MBT-DH and MBT-IOP are generally very similar (see Table 1 ), but the intensity of group therapy differs markedly: MBT-IOP involves two group therapy sessions per week, while MBT-DH entails a day hospital programme five days per week, with nine group therapy sessions per week.
Both MBT-DH and MBT-IOP were offered by therapists who had completed MBT training and received ongoing supervision in MBT. The three participating treatment sites had also successfully implemented MBT following criteria set out in the MBT quality manual (21) , including monitoring of adherence in daily practice by means of internal and external team supervision. To assess withinsession adherence to the model, three trained raters independently rated 20 randomly sampled taped treatment sessions (stratified for condition, setting, and treatment duration) using the MBT Adherence Scale (22) . Inter-rater reliability across the 20 tapes was high, with an average intraclass correlation coefficient of 0.87-0.99 for the subdomains and 0.94 for the total adherence score. Only one session was rated as "non-adherent" to the MBT model. The average total adherence score was 3.0 (SD=1.2) on a scale ranging from -3 to 9. Of all sessions, 42% were rated as "above adequate MBT", represented by a total score >3.5. No significant differences were found between conditions and treatment sites in terms of adherence.
Outcome measures
The primary outcome measure was symptom severity as assessed by the Global Severity Index (GSI) of the BSI (15, 16) The a priori power analysis was based on the GSI. With n=45 patients in each treatment arm, a superiority margin of d≥0.50 could be detected with one-sided testing, α=0.05, and 0.80 power (1) .
Statistical analyses
Differences in demographic and clinical features at baseline were investigated using two-tailed chisquare tests and independent sample t-tests, as appropriate. Treatment outcomes were examined over time using multilevel modelling in order to deal with the dependency of repeated measures within subjects over time and missing data in longitudinal follow-up using the XTMIXED procedure of Stata Statistical Software Release 12. All outcome analyses were based on intention-to-treat principles.
Time points were coded -3, -2, -1, and 0, implying that regression coefficients involving time measured the rate of change from baseline to 18 months after start of treatment and regression intercepts referenced group differences at the last time point. SSHI scores were log-transformed as they were highly positively skewed. Maximum likelihood was used to assess whether random or fixed slopes should be assumed in models for each outcome variable. Subsequently, quadratic and cubic time variables were added to the model if likelihood ratio tests showed significant improvement in fit.
Estimates and Cohen's d effect sizes (29) are based on predicted values.
There was a substantial proportion of missing data (range 12-52%), which was evenly distributed across the conditions. Although multilevel modelling is quite robust in dealing with missing data, we re-ran all analyses using state-of the-art data imputation procedures. Missing values were imputed using the multiple imputation software Amelia-2 (for R version 3.2.1+) in 10 datasets. These 10 imputed datasets were combined using Rubin's rules for combining estimates obtained from multiple imputed datasets (30) . Because estimated trajectories of change and effect sizes were highly similar for the imputed and non-imputed data, results based on the non-imputed data set are reported.
Results of the imputed data are available upon request from the first author.
Results
Between March 2009 and June 2014, 243 patients were referred to MBT in the participating treatment centres, of whom 114 met inclusion criteria and were randomized (see Figure 1 ). Table 2 shows demographic and clinical characteristics at baseline. There were no significant baseline differences between patients who were excluded and patients who were randomized. Treatment groups did not show any significant differences at baseline, except for self-harm. A greater number of patients assigned to MBT-IOP reported self-harm in the previous 6 months (χ²(1)=3.96, p<0.001), although there was no significant difference in reported frequency. Average treatment duration was slightly, although significantly, shorter in MBT-DH (M=14.3 months, SD=4.2) compared with MBT-IOP (M=15.9 months, SD=3.1), t(109)=2.223, p=0.028. The overall dropout rate was 12% (n=14), with no differences between the groups (n=5, 11% for MBT-IOP and n=9, 13% for MBT-DH), χ²(1)=0.056, p=0.813.
[Insert Figure 1] [Insert Table 2] Primary outcome Improvement over time between baseline and 18 months after start of treatment was significant, representing large effect sizes, in both MBT-IOP (d=0.83) and MBT-DH (d=1.16). There was no evidence for a differential rate of change between the two groups (β=-0.06, 95% CI=-0.19 to 0.07, z=-0.88, p=0.377). The between-group effect size of Cohen's d=0.34 indicated that MBT-DH was not superior to MBT-IOP in terms of improvements in symptom severity based on the a priori specified
Cohen's d≥0.5 margin (see Table 3 ).
[Insert Table 3 ]
Secondary outcomes
Significant improvements were observed on all secondary outcome measures 18 months after start of treatment, representing moderate to very large within-group effect sizes for both MBT-DH and MBT-IOP (see Table 3 ). For most secondary outcome measures, the differential rate of change between MBT-DH and MBT-IOP was not significant, with two exceptions, both in the domain of relational functioning. The differential rate of change was significantly larger for MBT-DH relational capacities as measured with the SIPP (β=0.12, 95% CI=0.02 to 0.22, z=2.26, p=0.024), and there was a similar trend for interpersonal problems as measured by the IIP (β=-7.40, 95% CI=-14.93 to 0.13, z=-1.93, p=0.056).
On secondary outcomes, between-group effect sizes consistently favoured MBT-DH, with multiple secondary outcome measures indicating MBT-DH to be superior to MBT-IOP at 18 months, defined as between-group differences ≥0.5. This was also the case on the PAI-BOR, which assesses core features of borderline pathology. However, both treatment groups showed similar improvements in terms of suicide attempts and self-harm, with medium to large effect sizes.
Discussion
This is the first study to compare the efficacy of two intensities of MBT for patients with BPD. Both treatment groups showed major improvements on primary and secondary outcome measures 18 months after start of treatment. Within-group effect sizes were for the most part large to very large and comparable to those found in other studies of MBT (6, [9] [10] [11] 13, 14) . Treatment dropout was relatively low (M=12%, n=14) compared with that reported in other RCTs of specialized BPD treatments (31) . Contrary to our hypothesis, MBT-DH was not superior to MBT-IOP in terms of reductions in symptom severity. However, MBT-DH showed a tendency towards superiority on most secondary outcomes, with medium to large between-group effect sizes (range d=0.51 to 1.82). Irrespective of the fact that there was no clear evidence for the superiority of MBT-DH 18 months after the start of treatment and irrespective of whether or not there is evidence for the superiority of MBT-DH at longer-term follow-up, the current findings suggest that patients in MBT-DH and MBT-IOP follow different trajectories of change, which may be important not only for patients but also for clinical decision-making.
Importantly, although patients in both MBT
There are a number of important limitations of this study that should be kept in mind when interpreting the results. First, the choice of symptom severity as our primary outcome measure was based upon the need to facilitate future comparison with treatment outcome in clinical practice by using a simple and widely used outcome measure. However, the BSI might not capture key BPD features. Therefore, we also included more specific BPD measures as secondary outcomes, including the PAI-BOR, the IIP and SIPP. Note, however, that the BSI was highly significantly correlated with the PAI-BOR in the current study (r=.73, p<.01). Second, although both MBT programmes were offered by certified therapists, treatment sites were monitored for adherence to MBT quality guidelines, and within-session adherence in individual therapy was monitored, important features of adherence to MBT (i.e., continuous adherence to the model at the level of programme organization and in group therapy) were not systematically measured in this study. The potential influence of these factors was somewhat mitigated, however, by the finding that there were no differences in withinsession adherence between MBT-DH and MBT-IOP and both treatments were offered by the same treatment services. Third, there was a considerable percentage of missing data in the study, particularly at follow-up assessments. However, the multiple imputation analyses yielded comparable results. Fourth, the superiority margin set in this study corresponded to a medium effect size. Smaller between-group differences may be clinically relevant, and thus further research is needed to address this issue. Fifth, the tendency of MBT-DH to be superior on secondary outcomes might reflect chance findings, particularly as there were no differences in terms of self-destructive behaviour. Findings of this study therefore need to be replicated, and longer-term follow-up is needed to investigate whether these differences are maintained in the longer term. Sixth, it cannot be ruled out that pharmacotherapy might have contributed to the observed improvements, as medication use over the course of treatment was not included in the analyses. However, there were no differences between the conditions in terms of the percentage of patients using medication at baseline and during treatment. Finally, randomization to the two conditions was skewed. However, there were no baseline differences between the two groups, with the exception of slightly higher levels of self-reported selfharm in MBT-IOP.
In conclusion, this study suggests that treatment intensity may have an effect on treatment outcomes in a specialized psychological treatment for BPD patients, at least 18 months after the start of treatment and in particular domains of functioning. This finding is important given the increasing financial pressure to develop less intensive treatments and the gradual discontinuation of highintensity programmes in clinical practice. The current findings suggest that such a policy may be premature, as there was a tendency for MBT-DH-the more intensive treatment-to be more effective than MBT-IOP on a range of secondary outcomes. Ultimately, longer-term follow-up and considerations concerning the cost-effectiveness of both treatments may be key in determining the optimal intensity of specialized treatments for BPD patients, such as MBT. This will be addressed in future reports.
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